Roth Capital Conference

Genesis Biopharma (OTC:GNBP), a biotechnology company developing targeted cancer therapies, today announced that Anthony Cataldo, President and Chief Executive Officer, and Marvin Hausman M.D., Chief Science Officer, will present to investors at the 23rd Annual Roth Capital Growth Stock Conference on Wednesday, March 16, 2011 at 2:00 p.m. Pacific. The conference is being held March 13-16 at the Ritz Carlton Hotel in Laguna Niguel, California. The company is a lightly traded stock that last traded on February 24, 2011 at a price of $1.26 per share. Genesis Biopharma has a market cap of $92 million and a 52-week range between $0.95 and $1.26 per share.

A webcast of the presentation will be accessible online at www.genesis-biopharma.com. An archived version will be available for 30 days.

Genesis Biopharma recently named Marvin S. Hausman M.D. as Chief Science Officer. Dr. Hausman has 30 years of drug development and clinical care experience at various pharmaceutical companies.

"We are very fortunate to have Marvin Hausman join the team at Genesis Biopharma," said Anthony J. Cataldo, President and Chief Executive Officer. "Dr. Hausman has an outstanding track record in identifying and developing breakthrough medical technologies, and in building companies. I believe his ability to form successful partnerships and strategic alliances will be an important asset as we grow the Company and create shareholder value."

Genesis Biopharma is a development-stage biotechnology company engaged in the development of targeted cancer therapies.

For more information about the company, visit www.genesis-biopharma.com.

Distributed by IntelBuilder Social Media Platform